Multiplexed Peptide-Based Fluorescent Probe Platform for Analysis of HER2-Positive Exosomal Membrane Proteins.
A urine test using fluorescent probes may non-invasively track HER2+ breast cancer status, though human studies are still needed to prove usefulness.
A peptide-based fluorescent probe platform was developed to selectively detect HER2-positive exosomes in cell lines, plasma, and urine, providing a potential non-invasive method for monitoring HER2+ breast cancer status. This represents promising early-stage technology development, but clinical validation with defined sensitivity/specificity in patient cohorts is required.
What the study was
- Study design
- Analytical chemistry proof-of-concept / technology development
- Population
- Cell-derived exosome samples + human plasma and urine
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Analytical chemistry
Why it surfaced
Novel sensing modality for exosomal liquid biopsy; Anal Chem is high-quality venue. Early stage; primarily in vitro with pilot human samples.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.